New York is currently home to 4494 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Global Patient Registry of Inherited Retinal Diseases
Recruiting
The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform patient management.
Gender:
ALL
Ages:
3 years and above
Trial Updated:
07/17/2025
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Inherited Retinal Diseases
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Recruiting
Nutritional status is a measurable and modifiable factor that is often not considered during treatment and its clinical impact undervalued due in part to the heavy demands on clinicians in low and middle income countries to deliver therapy to large numbers of patients. The proposed study will create a biobank of clinical data and biological specimens which will foster future studies on cancer progression and prognosis as well as toxicities during treatment which may impact survivorship and late-... Read More
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
07/17/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Acute Lymphoblastic Leukemia, Nutrition Aspect of Cancer, Microtia, Genetic Predisposition
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Recruiting
The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/17/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Hemolytic Disease of the Fetus and Newborn
HIIT Effects on Cardiometabolic Health
Recruiting
The primary aim of this randomized clinical trial is to compare the effects of three different HIIT protocols and a control group on cardiometabolic health in young adults with obesity. Participants will be randomly assigned to one of the following three groups, with each having varying work-to-rest ratios: 1) HIIT-A, 2) HIIT-B, 3) HIIT-C, and 4) control group. HIIT-A, HIIT-B, and HIIT-C groups will participate in six sessions of a running based HIIT program over a 2-week training period. Pre-cl... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
07/17/2025
Locations: Women's Building, Syracuse, New York
Conditions: Obesity, Cardiovascular Diseases, Metabolic Disease, High-intensity Interval Training
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Recruiting
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/17/2025
Locations: Clinical Research Alliance, Lake Success, New York
Conditions: Early Breast Cancer
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Recruiting
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of JNJ-78278343 with the combination agent in Part 2 (dose expansion).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Perlmutter Cancer Center at NYU Langone Brooklyn, Brooklyn, New York
Conditions: Metastatic Castration-resistant Prostate Neoplasms
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Recruiting
The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/17/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Ulcerative Colitis
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Cardiac Care & Vascular Medicine, PLLC, Bronx, New York
Conditions: Acute Coronary Syndrome
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/17/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/17/2025
Locations: Lincoln Hospital, Bronx, New York
Conditions: Ischemic Stroke; Ischemic Attack, Transient
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Recruiting
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Icahn School of Medicine at Mt. Sinai, New York, New York
Conditions: Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Recruiting
B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 150 adult... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Memorial Sloan Kettering Cancer Center-Koch Center /ID# 245459, New York, New York
Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma